ModernGraham Valuation

Company Name:

Company Ticker DVA Date of Analysis Davita Inc



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

6/1/2018

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$11,707,204,361	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	2.94	Pass
3.	Earnings Stability	Positive EPS for 10 years prior		Pass
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	80.25%	Pass
6.	Moderate PEmg Ratio	PEmg < 20	19.29	Pass
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	2.55	Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.				

1.	. Sufficiently Strong Financial Condition	Current Ratio > 1.5	2.94 Pass
2.	. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	1.62 Fail
3.	. Earnings Stability	Positive EPS for 5 years prior	Pass
4.	. Dividend Record	Currently Pays Dividend	Fail
5.	. Earnings Growth	EPSmg greater than 5 years ago	Pass
		Score	

Suitability

Defensive	Yes
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

	EPSmg		\$3.48
	MG Growth Estimate		2.95%
	MG Value		\$50.11
	MG Value based on 3% Growth		\$50.44
	MG Value based on 0% Growth		\$29.57
	Market Implied Growth Rate		5.39%
MG Opinion			
	Current Price		\$67.09
	% of Intrinsic Value		133.90%
	Opinion	Overvalued	
	MG Grade	C+	

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$30.17
Graham Number	\$47.61
PEmg	19.29
Current Ratio	2.94
PB Ratio	2.55
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	\$3.92	Next Fiscal Year Estimate	\$3.48
Dec2017	\$3.47	Dec2017	\$3.19
Dec2016	\$4.29	Dec2016	\$3.01
Dec2015	\$1.25	Dec2015	\$2.43
Dec2014	\$3.33	Dec2014	\$2.91
Dec2013	\$2.95	Dec2013	\$2.61
Dec2012	\$2.74	Dec2012	\$2.36
Dec2011	\$2.48	Dec2011	\$2.11
Dec2010	\$1.97	Dec2010	\$1.88
Dec2009	\$2.03	Dec2009	\$1.76
Dec2008	\$1.77	Dec2008	\$1.55
Dec2007	\$1.78	Dec2007	\$1.37
Dec2006	\$1.37	Dec2006	\$1.11
Dec2005	\$1.10	Dec2005	\$0.92
Dec2004	\$1.08	Dec2004	\$0.76
Dec2003	\$0.78	Dec2003	\$0.48
Dec2002	\$0.61	Dec2002	\$0.26
Dec2001	\$0.48	Balance Sheet Information	3/1/2018
Dec2000	\$0.05	Total Current Assets	\$8,673,555,000
Dec1999	-\$0.60	Total Current Liabilities	\$2,947,523,000
Dec1998	-\$0.04	Long-Term Debt	\$9,279,885,000
		Total Assets	\$18,942,372,000
		Intangible Assets	\$6,751,958,000
		Total Liabilities	\$14,160,291,000
		Shares Outstanding (Diluted Average)	181,835,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other	Davita Inc Valuation – February 2017 \$DVA
ModernGraham posts about the company	DaVita HealthCare Partners Inc Valuation – November 2015 Update \$DVA
	30 Companies in the Spotlight This Week - 11/15/14
	DaVita Healthcare Partners Inc. Annual Valuation – 2014 \$DVA

 Other ModernGraham posts about related companies
 Danaher Corp Valuation – May 2018 \$DHR

 Agilent Technologies Inc Valuation – May 2018 \$A
 Cooper Companies Inc Valuation – May 2018 \$COO

 Edwards Lifesciences Corp Valuation – May 2018 \$EW
 Baxter International Inc Valuation – May 2018 \$BAX

 Boston Scientific Corp Valuation – May 2018 \$BSX
 Centene Corp Valuation – May 2018 \$BSX

 Centene Corp Valuation – May 2018 \$CNC
 Abbott Laboratories Valuation – May 2018 \$BDX

 IQVIA Holdings Inc Valuation – Initial Coverage May 2018 \$IQV